RT Journal Article
T1 The Value of In Vitro Tests to DiminishDrug Challenges.
A1 Mayorga, Cristobalina
A1 Doña, Inmaculada
A1 Perez-Inestrosa, Ezequiel
A1 Fernandez, Tahia D
A1 Torres, Maria J
K1 IgE
K1 T-cells
K1 allergy
K1 basophils
K1 cytokines
K1 diagnosis
K1 drug
K1 hypersensitivity
K1 immunoassays
K1 in vitro
AB Drug hypersensitivity reactions have multiple implications for patient safety and health system costs, thus it is important to perform an accurate diagnosis. The diagnostic procedure includes a detailed clinical history, often unreliable; followed by skin tests, sometimes with low sensitivity or unavailable; and drug provocation testing, which is not risk-free for the patient, especially in severe reactions. In vitro tests could help to identify correctly the responsible agent, thus improving the diagnosis of these reactions, helping the physician to find safe alternatives, and reducing the need to perform drug provocation testing. However, it is necessary to confirm the sensitivity, specificity, negative and positive predictive values for these in vitro tests to enable their implementation in clinical practice. In this review, we have analyzed these parameters from different studies that have used in vitro test for evaluating drug hypersensitivity reactions and estimated the added value of these tests to the in vivo diagnosis.
PB MDPI
YR 2017
FD 2017-06-02
LK http://hdl.handle.net/10668/11277
UL http://hdl.handle.net/10668/11277
LA en
NO Mayorga C, Doña I, Perez-Inestrosa E, Fernández TD, Torres MJ. The Value of In Vitro Tests to DiminishDrug Challenges. Int J Mol Sci. 2017 Jun 7;18(6):1222
NO We thank James R. Perkins for his help with the final English language version of this manuscript. The present study has been supported by Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofunded by European Regional Development Fund (ERDF): PI12/02529, PI15/01206, RETICs RIRAAF (RD12/0013/0001 and RD12/0013/0003) and ARADyAL (RD16/0006/0001 and RD16/0006/0012); the Ministry of Economy and Competitiveness (grants cofunded by European Regional Development Fund(ERDF): CTQ2016-75870-P) and by Andalusian Regional Ministry of Economy and Knowledge (grants cofunded by European Regional Development Fund (ERDF): CTS-06603); Andalusian Regional Ministry Health (grants: PI-0179-2014, PI-0241-2015 and PI-0250-2016). TD Fernandez holds a “Ramon y Cajal” research contract by Ministry of Economy and Competitiveness (RYC-2013-13138). C Mayorga holds a “Nicolas Monardes” research contract by Andalusian Regional Ministry Health: C-0044-2012 SAS 2013. I Doña holds a “Joan Rodes” research contract (JR15/00036) supported by Institute of Health “Carlos III” of the Ministry of Economy and Competitiveness (grants cofunded by European Social Fund (ESF)).
DS RISalud
RD Apr 10, 2025